← All organizations
Highest phase reached
Phase 4
Timeline
1990s
- Jul 1, 1998
Corcept Therapeutics— Founded
2010s
- Feb 17, 2012
mifepristone— NDA Secondary Org
Drugs by trial phase (29 distinct, 72 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (11 own, 0 via acquisition)
Indications
Studied for
- ACTH-Secreting Pituitary Adenoma
- Adenocarcinoma
- Adenoma
- Adrenal Insufficiency
- Adrenocortical Adenoma
- Adrenocortical Carcinoma
- Adrenocortical Hyperfunction
- Alzheimer Disease
- Body Weight
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Transitional Cell
- Cushing Syndrome
- Depression
- Depressive Disorder
- Disease
- Fatty Liver
- Lung Neoplasms
- Major Depressive Disorder
- Mental Disorders
- Neoplasms
- Non-alcoholic Fatty Liver Disease
- Ovarian Neoplasms
- Pituitary ACTH Hypersecretion
- Prostatic Neoplasms
- Psychotic Disorders
- Sarcoma
- Schizophrenia
- Signs and Symptoms
- Syndrome
- Triple Negative Breast Neoplasms
- Weight Gain
Marketed drugs (1)
Recent trials (50)
- NCT07259317Lead sponsorPhase 2Dec 31, 2025
- NCT07276373OfficialPhase 1/Phase 2Dec 31, 2025
- NCT07276373Lead sponsorPhase 1/Phase 2Dec 31, 2025
- NCT07259317OfficialPhase 2Dec 31, 2025
- NCT07240116OfficialPhase 1Sep 11, 2025
- NCT07240116Lead sponsorPhase 1Sep 11, 2025
- NCT06947304OfficialPhase 1Aug 22, 2025
- NCT06947304Lead sponsorPhase 1Aug 22, 2025
- NCT06906341Lead sponsorPhase 2Apr 11, 2025
- NCT06906341OfficialPhase 2Apr 11, 2025
- NCT06689254CollaboratorPhase 2Nov 15, 2024
- NCT06928779Lead sponsorPhase 1Oct 8, 2024
- NCT06928779OfficialPhase 1Oct 8, 2024
- NCT06495944Lead sponsorPhase 1May 31, 2024
- NCT06495944OfficialPhase 1May 31, 2024
Details
- Founded
- Menlo Park, CA, US Jul 1, 1998
- Last known activity
- Mar 25, 2026